Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: lebreton c. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
[Thyroid carcinoma on struma ovarii: Diagnosis and treatment].
Lebreton C, Al Ghuzlan A, Floquet A, Kind M, Leboulleux S, Godbert Y. Lebreton C, et al. Bull Cancer. 2018 Mar;105(3):281-289. doi: 10.1016/j.bulcan.2017.11.014. Epub 2018 Feb 17. Bull Cancer. 2018. PMID: 29459090 Review. French.
Update on new treatments for rare ovarian tumours.
Quesada S, Bini M, Lebreton C, Ray-Coquard I. Quesada S, et al. Among authors: lebreton c. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):27-33. doi: 10.1097/GCO.0000000000000836. Epub 2022 Nov 18. Curr Opin Obstet Gynecol. 2023. PMID: 36440753 Free PMC article. Review.
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer.
Davidson TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, Larson MC, Oberg AL, Provencher DM, Glaspy JA, Karlan BY, Slamon DJ, Konecny GE, Ray-Coquard IL. Davidson TM, et al. Among authors: lebreton cl. Gynecol Oncol. 2023 Mar;170:221-228. doi: 10.1016/j.ygyno.2023.01.021. Epub 2023 Jan 27. Gynecol Oncol. 2023. PMID: 36709663 Free PMC article. Clinical Trial.
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups].
Collineau B, Genestie C, Croce S, Meeus P, Floquet A, Guyon F, Llacer-Moscardo C, Lebreton C, Taieb S, Toulmonde M, Blay JY, Bonvalot S, Ray-Coquard I, Pautier P, Duffaud F. Collineau B, et al. Among authors: lebreton c. Bull Cancer. 2023 Apr;110(4):440-449. doi: 10.1016/j.bulcan.2023.01.009. Epub 2023 Feb 28. Bull Cancer. 2023. PMID: 36863922 Review. French.
[Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group].
Lebreton C, Meeus P, Genestie C, Croce S, Guyon F, Moscardo CL, Taieb S, Blay JY, Bonvalot S, Bompas E, Chevreau C, Lécuru F, Rossi L, Joly F, Rios M, Chaigneau L, Duffaud F, Pautier P, Ray-Coquard I. Lebreton C, et al. Bull Cancer. 2023 Jul-Aug;110(7-8):844-854. doi: 10.1016/j.bulcan.2023.03.003. Epub 2023 Mar 27. Bull Cancer. 2023. PMID: 36990895 Review. French.
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. Among authors: lebreton c. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
[Treatments for rare ovarian tumors: What's new?].
Lebreton C, Quesada S, Bini M, Babin G, Rossi L, Chopin N, Croce S, Hartog C, Renaud T, Gaillard AL, Petit A, Serre AA, Trédan O, Rowinski E, Cockenpot V, Treilleux I, Rousset-Jablonski C, Méeus P, Guyon F, Ray-Coquard I. Lebreton C, et al. Bull Cancer. 2023 Jul-Aug;110(7-8):818-824. doi: 10.1016/j.bulcan.2023.03.007. Epub 2023 Apr 10. Bull Cancer. 2023. PMID: 37045734 French.
Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: Incidence and impact of bone mineral density.
Duranson A, Thevenet V, Guyon F, Babin G, Lebreton C, Renaud T, Gaillard AL, Dupuy Q, Bouleftour W, Magne N, Petit A. Duranson A, et al. Among authors: lebreton c. Clin Transl Radiat Oncol. 2023 Jun 12;41:100650. doi: 10.1016/j.ctro.2023.100650. eCollection 2023 Jul. Clin Transl Radiat Oncol. 2023. PMID: 37441540 Free PMC article.
100 results